Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog

被引:51
作者
Benedetti, MS
Coupez, R
Whomsley, R
Nicolas, JM
Collart, P
Baltes, E
机构
[1] UCB Bioprod SA, Pharma Sector, Dept Global Prod Safety & Metab, F-92003 Nanterre, France
[2] UCB Bioprod SA, Pharma Sector, Dept Global Prod Safety & Metab, B-1420 Braine lAlleud, Belgium
关键词
D O I
10.1080/0049825042000196749
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The pharmacokinetics and metabolism of C-14-levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog after a single oral dose were investigated. Moreover, the in vitro hydrolysis of levetiracetam to its major carboxylic metabolite by rat tissue homogenates was investigated to identify tissues involved in the production of the metabolite. Data are also presented on the induction of the enzyme(s) involved in levetiracetam hydrolysis in the rat. 2. Levetiracetam was rapidly and almost completely absorbed. The unchanged drug accounted for a very high percentage of plasma radioactivity. Levetiracetam did not bind to plasma proteins. Although brain radioactivity concentrations were lower than those of whole blood at early time points, brain-to-blood ratios increased over time. The predominant route of elimination of total C-14 was excretion via urine, accounting for about 81, 93, 87 and 89% of the dose in the mouse, rat, rabbit and dog, respectively. Consequently, levetiracetam was poorly metabolized. It was submitted in vivo to hydrolysis and/or oxidation. Hydrolysis of the amide function of levetiracetam produced the corresponding acid. However, levetiracetam could also be oxidized at positions 3 and 4 of the 2-oxopyrrolidine ring. Finally, the compound and the corresponding acid metabolite could be oxidized at position 5 of the 2-oxopyrrolidine ring and then hydrolysed with the opening of the ring. 3. All the investigated rat tissues (liver, kidney, lung, brain, small intestine mucosa) had the potential to produce the acid metabolite. By contrast, the acid was undetectable following incubation of levetiracetam with buffer alone or heat-denaturated liver fractions. 4. No marked species or sex differences were observed in the absorption, disposition and metabolism of levetiracetam. 5. The hydrolysis of levetiracetam is carried out by an enzymatic process characterized by a broad tissue distribution. In the rat, the enzyme system hydrolysing levetiracetam is not induced by phenobarbital, at least under the experimental conditions used herein, whereas the enzyme system(s) involved in the other metabolic pathways is induced.
引用
收藏
页码:281 / 300
页数:20
相关论文
共 27 条
  • [1] ADUSUMALLI VE, 1991, DRUG METAB DISPOS, V19, P1116
  • [2] ALI B, 1983, J PHARMACOL EXP THER, V226, P589
  • [3] Pharmacokinetics and metabolism of 14C-levetiracetam, a new antlepileptic agent, in healthy volunteers
    Benedetti, MS
    Whomsley, R
    Nicolas, JM
    Young, C
    Baltes, E
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 621 - 630
  • [4] INTERSPECIES PHARMACOKINETIC SCALING AND THE DEDRICK PLOTS
    BOXENBAUM, H
    RONFELD, R
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1983, 245 (06): : R768 - R775
  • [5] Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat
    Doheny, HC
    Ratnaraj, N
    Whittington, MA
    Jefferys, JGR
    Patsalos, PN
    [J]. EPILEPSY RESEARCH, 1999, 34 (2-3) : 161 - 168
  • [6] DOHENY MH, 1994, EPILEPSIA, V35, P85
  • [7] ANIMAL PHARMACOKINETICS AND INTERSPECIES SCALING OF FCE-22101, A PENEM ANTIBIOTIC
    EFTHYMIOPOULOS, C
    BATTAGLIA, R
    BENEDETTI, MS
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (04) : 517 - 526
  • [8] GOBERT J, 1975, S NOOTR UCB S A BRUS, P1
  • [9] NONLINEAR TISSUE DISPOSITION - SALICYLIC-ACID IN RAT-BRAIN
    GONZALEZ, MA
    TOZER, TN
    CHANG, DTT
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1975, 64 (01) : 99 - 103
  • [10] UCB L059, A NOVEL ANTICONVULSANT DRUG - PHARMACOLOGICAL PROFILE IN ANIMALS
    GOWER, AJ
    NOYER, M
    VERLOES, R
    GOBERT, J
    WULFERT, E
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 222 (2-3) : 193 - 203